ARTV (Artiva Biotherapeutics) EBIT per Share : $-3.33 (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics EBIT per Share?

Artiva Biotherapeutics's EBIT per Share for the three months ended in Mar. 2025 was $-0.91. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.33.

During the past 3 years, the average EBIT per Share Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Artiva Biotherapeutics's EBIT per Share or its related term are showing as below:

ARTV' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -1.6 Med: 5.35 Max: 12.3
Current: -1.6

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Artiva Biotherapeutics was 12.30% per year. The lowest was -1.60% per year. And the median was 5.35% per year.

ARTV's 3-Year EBIT Growth Rate is ranked worse than
62.9% of 1221 companies
in the Biotechnology industry
Industry Median: 9.3 vs ARTV: -1.60

Artiva Biotherapeutics's EBIT for the three months ended in Mar. 2025 was $-22.17 Mil.

Artiva Biotherapeutics EBIT per Share Historical Data

The historical data trend for Artiva Biotherapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics EBIT per Share Chart

Artiva Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-1.90

-7.67

-6.39

-1.32

-5.98

Artiva Biotherapeutics Quarterly Data
	Dec19	Dec20	Mar21	Sep21	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT per Share	Get a 7-Day Free Trial											-0.62	-0.70	-0.97	-0.75	-0.91

Artiva Biotherapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Artiva Biotherapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-67.282	/	11.259
=	-5.98

Artiva Biotherapeutics's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

	EBIT per Share		(Q: Mar. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-22.171	/	24.342
=	-0.91

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.33

Artiva Biotherapeutics (NAS:ARTV) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Artiva Biotherapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Artiva Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.artivabio.com

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).